Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Nephrol Ther ; 16(2): 97-104, 2020 Mar.
Article in French | MEDLINE | ID: mdl-31987729

ABSTRACT

OBJECTIVE: To describe the incidence and risks factors of ART induced nephrotoxicity and chronic kidney disease in HIV-1-infected adults with low body mass index (<18.5kg/m2). METHODS: A retrospective cohort study at the Ambulatory Treatment Center in Brazzaville, Congo. Patients with estimated glomerular filtration rate decrease by 25% compared to baseline or a 0.5mg/dL increase in serum creatinine above baseline were classified as having nephrotoxicity, and chronic kidney disease was defined as a value less than 60mL/min/1.73m2. We used Cox proportional hazards regression models to determine factors associated with nephrotoxicity and chronic kidney disease. RESULTS: Of 325 patients, 73.23% were women. Median values were an age 37.55 years (IQR: 33.51-44.96), weight 45kg (IQR: 41-49), CD4 count 137.5 cells/µL (42-245). In the first 24-months, follow-up on ART incidence rate of nephrotoxicity and chronic kidney disease was 27.95 and 7.44 per 100 persons-year respectively. Multivariate analysis identified as a risk factor of nephrotoxicity, baseline haemoglobin below or equal 8g/dL (aHR=2.25; 95%CI 1.28-3.98; P=0.005) and the use of tenofovir (aHR=1.51; 95%CI 1.01-2.27; P=0.04). DFG between 60-80 mL/min/1.73 m2 (aHR=0.35; 95%CI 0.21-0.59; P<0.001) and 45-59mL/min/1.73 m2 (aHR=0.10; 95%CI 0.01-0.72; P=0.02) was not a contraindication for initiating antiretroviral therapy. Each 10-year older age was associated with an increased risk of developing chronic kidney disease (aHR=1.95; 95%CI 1.2-3.17; P=0.007). CONCLUSION: Incidence of nephrotoxicity and chronic kidney disease were high. African HIV-positive patient with low body mass index at baseline need close monitoring of their renal function when treated with tenofovir.


Subject(s)
Antiviral Agents/adverse effects , Body Mass Index , HIV Infections/drug therapy , Kidney Diseases/chemically induced , Kidney Diseases/epidemiology , Tenofovir/adverse effects , Adult , Antiviral Agents/therapeutic use , Cohort Studies , Congo , Female , Humans , Incidence , Male , Renal Insufficiency, Chronic/chemically induced , Renal Insufficiency, Chronic/epidemiology , Retrospective Studies , Risk Factors , Tenofovir/therapeutic use
2.
J Infect Dis ; 196 Suppl 2: S184-92, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17940948

ABSTRACT

Ebola virus (EBOV) has caused outbreaks of severe viral hemorrhagic fever in regions of Central Africa where medical facilities are ill equipped and diagnostic capabilities are limited. To obtain a reliable test that can be implemented easily under these conditions, monoclonal antibodies to the EBOV matrix protein (VP40), which previously had been found to work in a conventional enzyme-linked immunosorbent assay, were used to develop an immunofiltration assay for the detection of EBOV antigen in chemically inactivated clinical specimens. The assay was evaluated by use of defined virus stocks and specimens from experimentally infected animals. Its field application was tested during an outbreak of Ebola hemorrhagic fever in 2003. Although the original goal was to develop an assay that would detect all EBOV species, only the Zaire and Sudan species were detected in practice. The assay represents a first-generation rapid field test for the detection of EBOV antigen that can be performed in 30 min without electrical power or expensive or sensitive equipment.


Subject(s)
Antigens, Viral/analysis , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/immunology , Adolescent , Adult , Antibodies, Monoclonal , Child , Democratic Republic of the Congo/epidemiology , Disease Outbreaks , Female , Hemorrhagic Fever, Ebola/epidemiology , Humans , Infant , Male , Reproducibility of Results
3.
Am J Trop Med Hyg ; 73(2): 428-34, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16103616

ABSTRACT

This report describes the first reported outbreak of human monkeypox in the Republic of Congo. Eleven confirmed and probable monkeypox cases were observed during this outbreak, all were less than 18 years old, and most resided on the grounds of the Government Hospital in Impfondo. Molecular, virologic, and serologic, and diagnostic assays were used to detect evidence of monkeypox (or orthopox) virus infection in individuals with striking dermatologic and other clinical manifestations. The majority of cases in this outbreak experienced significant, symptomatic illnesses; there was one death, possibly involving secondary complications, and one instance of profound sequelae. Up to six sequential transmissions of monkeypox virus from person to person are hypothesized to have occurred, making this the longest uninterrupted chain of human monkeypox fully documented to date. The pattern of sustained human-to-human transmission observed during this outbreak may influence our current perception of the capacity for this zoonotic virus to adapt to humans.


Subject(s)
Disease Outbreaks , Hospitals , Monkeypox virus/isolation & purification , Mpox (monkeypox)/transmission , Adolescent , Adult , Animals , Child , Child, Preschool , Congo , Democratic Republic of the Congo/epidemiology , Female , Humans , Infant , Male , Mpox (monkeypox)/diagnosis , Mpox (monkeypox)/pathology , Mpox (monkeypox)/virology , Monkeypox virus/genetics , Monkeypox virus/immunology , Monkeypox virus/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...